The Biomedical Advanced Research and Development Authority (BARDA) has awarded $72 million to three vaccine companies to boost H5N1 vaccine production. CSL Seqirus, producing a cell-based vaccine, ...

Federal scientists are closely studying H5N1 genetic sequences from California dairy workers in search of any dangerous ...

There are currently no licensed vaccines or drugs to prevent or treat Marburg, but experimental versions are heading to ...

The firm will enter studies this month aimed at obtaining CLIA waiver for its FDA-cleared FebriDx assay to distinguish bacterial from non-bacterial infections.

There are currently no recommendations for anyone to be vaccinated against bird flu and federal health officials note this is ...

Although California dairy farmers anticipated a bird flu mortality rate of less than 2%, some say between 10% and 15% of ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

Gigagen Inc., a subsidiary of Grifols SA, has been awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a recombinant polyclonal antibody therapy ...

A sliver-plated wound dressing made by Bravida Medical and funded by BARDA is already approved for treating mustard ...

State officials say a dairy worker in the Central Valley likely contracted H5N1 bird flu. They say the risk of infection ...

An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer’s ...